{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:18:07Z","timestamp":1782656287903,"version":"3.54.5"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sporadic inclusion body myositis (IBM) is an acquired muscle disease and the most common idiopathic inflammatory myopathy over the age of 50. It is characterized by male predominance, with a prevalence rate between 1 and 71 cases per million, reaching 139 cases per million over the age of 50 globally. The diagnosis of IBM is based on clinical presentation and muscle biopsy findings. However, there is increasing evidence for the role of genetics and serum biomarkers in supporting a diagnosis. Antibodies against the cytosolic 5\u2032-nucleotidase 1A (Anti-CN1A), an enzyme catalyzing the conversion of adenosine monophosphate into adenosine and phosphate and is abundant in skeletal muscle, has been reported to be present in IBM and could be of crucial significance in the diagnosis of the disease. In this study, we investigated the diagnostic accuracy of anti-CN1A antibodies for sporadic IBM in comparison with other inflammatory myopathies, autoimmune disorders, motor neurone disease, using a hierarchical bivariate approach, and a Bayesian model taking into account the variable prevalence. The results of the present analysis show that anti-CN1A antibodies have moderate sensitivity, and despite having high specificity, they are not useful biomarkers for the diagnosis of IBM, polymyositis or dermatomyositis, other autoimmune conditions, or neuromuscular disorders. Neither the hierarchical bivariate nor the Bayesian analysis showed any significant usefulness of anti-CN1A antibodies in the diagnosis of IBM.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000353","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T15:02:32Z","timestamp":1629903752000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis"],"prefix":"10.1097","volume":"23","author":[{"given":"Ioannis","family":"Mavroudis","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Knights","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foivos","family":"Petridis","sequence":"additional","affiliation":[{"name":"Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symela","family":"Chatzikonstantinou","sequence":"additional","affiliation":[{"name":"Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Karantali","sequence":"additional","affiliation":[{"name":"Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kazis","sequence":"additional","affiliation":[{"name":"Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","article-title":"Prevalence of sporadic inclusion body myositis in Western Australia","volume":"23","author":"Phillips","year":"2000","journal-title":"Muscle Nerve."},{"key":"R2-20250507","first-page":"34","article-title":"Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul\/Turkey: a muscle biopsy based survey","volume":"30","author":"Oflazer","year":"2011","journal-title":"Acta Myol."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in The Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology."},{"key":"R4-20250507","first-page":"445","article-title":"Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota","volume":"35","author":"Wilson","year":"2008","journal-title":"J Rheumatol."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.410400407","article-title":"Inclusion body myositis: clinical and pathological boundaries","volume":"40","author":"Amato","year":"1996","journal-title":"Ann Neurol."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11940-000-0019-9","article-title":"Inclusion body myositis","volume":"2","author":"Barohn","year":"2000","journal-title":"Curr Treat Options Neurol."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00207454.2018.1527329","article-title":"A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab","volume":"129","author":"Ioannis","year":"2019","journal-title":"Int J Neurosci."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0404.1994.tb01647.x","article-title":"Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases","volume":"89","author":"Lindberg","year":"1994","journal-title":"Acta Neurol Scand."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00186623","article-title":"Inclusion body myositis: clinical and histopathological features of 36 patients","volume":"71","author":"Beyenburg","year":"1993","journal-title":"Clin Investig."},{"key":"R12-20250507","first-page":"1385","article-title":"Inclusion body myositis: analysis of 32 cases","volume":"19","author":"Sayers","year":"1992","journal-title":"J Rheumatol."},{"key":"R13-20250507","first-page":"1871","article-title":"Inclusion body myositis","volume":"22","author":"Greenberg","year":"2016","journal-title":"Continuum (Minneap Minn)."},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","article-title":"Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients","volume":"252","author":"Badrising","year":"2005","journal-title":"J Neurol."},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp-2013-307051","article-title":"GNE myopathy: current update and future therapy","volume":"86","author":"Nishino","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-007-0224-7","article-title":"Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy","volume":"114","author":"Guinto","year":"2007","journal-title":"Acta Neuropathol."},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol."},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain."},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord."},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med."},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biostatistics\/kxl004","article-title":"A unification of models for meta-analysis of diagnostic accuracy studies","volume":"8","author":"Harbord","year":"2007","journal-title":"Biostatistics."},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/sim.4780122405","article-title":"A bivariate approach to meta-analysis","volume":"12","author":"Van Houwelingen","year":"1993","journal-title":"Stat Med."},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/096228020101000404","article-title":"Bayesian methods in meta-analysis and evidence synthesis","volume":"10","author":"Sutton","year":"2001","journal-title":"Stat Methods Med Res."},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc."},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jclinepi.2006.06.011","article-title":"Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach","volume":"59","author":"Chu","year":"2006","journal-title":"J Clin Epidemiol."},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2017.07.002","article-title":"Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts","volume":"472","author":"Muro","year":"2017","journal-title":"Clin Chim Acta."},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol."},{"key":"R31-20250507","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One."},{"key":"R32-20250507","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol."},{"key":"R33-20250507","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R34-20250507","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:03:48Z","timestamp":1746651828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000353","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}